Mutations that activate epidermal growth factor receptor (EGFR) are prevalent in NSCLC (2, 3), and patients with tumors harboring EGFR driver mutations generally respond well to initial treatment using EGFR inhibitors (EGFRi). Here, EGFR is linked to non-small cell lung carcinoma.